 Outlook Therapeutics Inc NASDAQ:OTLK said it has re-submitted its biologics license application BLA to the US Food and Drug Administration FDA for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as LYTENAVA bevacizumab-vikg for the treatment of wet age-related macular degeneration wet AMD. Outlook Therapeutics CEO Russell Trenary said the company has worked diligently over the past three months to provide additional required information not included in its March 2022 submission. 